Sanofi

Aventis Pharmaceuticals Inc.

Christopher Loren Vandeusen

Sukanthini Thurairatnam

John Ziqi Jiang

Jeffrey Stephen Sabol

Lan Mu

Suzanne C Aldous

Barbara S Rauckman

Brian L Pedgrift

Liang Ma

Stanly John

Jinqi Lu

Harry Randall Munson

James R Pribish

Michael W Fennie

Grzegorz T Stoklosa

This invention is directed to a compound of formula (I): wherein R1, R2 and R3 are as defined herein, a pharmaceutical composition comprising the compound, intermediates and processes for making said compounds, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma, chronic obstructive pulmonary disease (COPD) and age-related macular degeneration (AMD).

Phenyloxadiazole derivatives as PGDS inhibitors

This invention is directed to a compound of formula (I): wherein R, R, R, Rand Lare as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD).

Pyrimidine hydrazide compounds as PGDS inhibitors

This invention is directed to a compound of formula (I): wherein R, R, Rand Lare as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD).

Pyrimidine amide compounds as PGDS inhibitors

Growing community of inventors

East Windsor, NJ, United States of America

Christopher Loren Vandeusen